Showing results (111-120 of 153) with videos related to
Sort By:
Pageof 16
BMC Medicine|December 17, 2009
A systems analysis of the chemosensitivity of breast cancer cells to the polyamine analogue PG-11047Wen-Lin Kuo, Debopriya Das, Safiyyah Ziyad, et al.BMC Cancer|January 23, 2008
Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalitiesJoshua Z Press, Alessandro De Luca, Niki Boyd, et al.Plos One|April 6, 2012
Integrated analyses of microRNAs demonstrate their widespread influence on gene expression in high-grade serous ovarian carcinomaChad J Creighton, Anadulce Hernandez-Herrera, Anders Jacobsen, et al.BMC Medical Genomics|February 21, 2009
High quality copy number and genotype data from FFPE samples using Molecular Inversion Probe (MIP) microarraysYuker Wang, Victoria E H Carlton, George Karlin-Neumann, et al.Nature Medicine|April 5, 2011
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapyEric A Collisson, Anguraj Sadanandam, Peter Olson, et al.BMC Bioinformatics|November 8, 2006
A simple spreadsheet-based, MIAME-supportive format for microarray data: MAGE-TABTim F Rayner, Philippe Rocca-Serra, Paul T Spellman, et al.Plos One|July 17, 2015
Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast CancerJames E Korkola, Eric A Collisson, Laura Heiser, et al.The Journal of Clinical Investigation|February 1, 2024
HER2 heterogeneity and treatment response-associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trialZheqi Li, Otto Metzger Filho, Giuseppe Viale, et al.Cancer Cell|December 13, 2006
Genomic and transcriptional aberrations linked to breast cancer pathophysiologiesKoei Chin, Sandy DeVries, Jane Fridlyand, et al.Plos One|October 12, 2017
Correction: Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast CancerJames E Korkola, Eric A Collisson, Laura M Heiser, et al.Pageof 16